SFDA Medical Device Registration in Saudi Arabia: MDMA Requirements and Process

Medical device registration in Saudi Arabia is not a single filing event. It is a connected series of decisions: whether the product is a medical device, its intended purpose and risk class, which party owns submission and follow-up duties, and whether the technical documentation supports the claims intended for the Saudi market. An early error can later become a major evidence gap.

1. Define the product scope before discussing MDMA

Build a controlled description covering the legal manufacturer, principle of operation, intended purpose, users, target patient or specimen, use environment, models, accessories, and claims. Software, accessories, and IVD components may require separate analysis. A trade name alone is not enough because qualification and classification depend on function, claims, and clinical consequences.

2. Establish classification and rationale

The manufacturer is responsible for classification under the Saudi rules. Every plausible rule should be tested, with the highest resulting class applied where more than one rule is relevant. The rationale must remain consistent with the intended purpose, labeling, instructions for use, and risk-management file.

3. Map the responsible parties in Saudi Arabia

Confirm the legal manufacturer, applicant, required establishment licenses, and Authorized Representative role where applicable. Keep regulatory representation distinct from importation and distribution: each activity carries its own licensing and operational responsibilities.

4. Build traceable technical documentation

MDS-REQ 1 requires the manufacturer to prepare, retain, and update technical documentation demonstrating conformity with the Essential Principles of Safety and Performance. Readiness is measured by whether each claim and risk can be traced to suitable evidence and a justified conclusion.

• Device description, configurations, models, accessories, and intended purpose.
• Classification rationale, Essential Principles checklist, and conformity methods.
• Design, manufacturing, and lifecycle risk-management information.
• Verification and validation appropriate to the device, including performance, safety, biocompatibility, sterilization, shelf life, and software where applicable.
• Clinical evaluation or IVD performance evaluation proportionate to claims and risks.
• Labeling, instructions, and post-market, vigilance, and change-control planning.

5. Submission is not the end of the process

The application is submitted electronically through the official channel after the relevant party and licensing prerequisites are met. Portal labels, fields, fees, and review mechanics can change, so verify them at filing instead of copying historic figures from articles or proposals.

6. Prepare for technical questions before they arrive

Review consistency across model names, intended purpose, classification, performance claims, risk controls, test evidence, controlled labeling, and party responsibilities. Convert each issue into a gap register with impact, priority, owner, action, and closure criterion.

7. Maintain compliance after authorization

MDMA does not end the lifecycle. Information and licenses must remain current; changes must be assessed; complaints and incidents monitored; UDI, labeling, and post-market duties met where applicable; and actual commercial activities covered by the appropriate licenses.

How Basier supports readiness

Basier confirms product scope, tests classification and pathway, maps responsible parties, reviews dossier architecture, prioritizes gaps, and builds a closure and submission plan. This is not a promise of approval; it is a disciplined way to make the dossier more coherent and defensible.

References: [1] [2] [3]